Scholarlink

<p>In 2024, the current ESC guidelines for the management of atrial fibrillation (AF) were published. Despite significant advances in the prevention, diagnosis and treatment of AF, it remains the most common sustained arrhythmia with a&#xa0;significant impact on patients, their caregivers and public health. The concise guidelines focus on evidence-based recommendations and their practical implementation supported by clear figures and treatment pathways. The holistic care for AF patients including their comorbidities is prioritized in a&#xa0;comprehensive AF-CARE concept. It comprises “C”&#xa0;for comorbidities and risk factor management, “A”&#xa0;for avoidance of stroke and thromboembolism, “R”&#xa0;for reduction of symptoms by rate and rhythm control and “E”, evaluation and dynamic reassessment. Ablation is now the first-line therapy in paroxysmal AF. Current data on device detected AF and triggered AF are considered. Maximum involvement of the patient for informed, shared decision-making is suggested, supported by the parallel publication of patient guidelines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Update der ESC-Vorhofflimmerleitlinien 2024

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Renate B. Schnabel,
  • Melanie Anuscha Gunawardene,
  • Christian Andreas Perings,
  • Daniel Steven,
  • Hans-Jörg Busch,
  • Isabel Deisenhofer,
  • Karl Georg Häusler,
  • Philipp Sommer,
  • Ralf Birkemeyer,
  • Lars Eckardt

摘要

In 2024, the current ESC guidelines for the management of atrial fibrillation (AF) were published. Despite significant advances in the prevention, diagnosis and treatment of AF, it remains the most common sustained arrhythmia with a significant impact on patients, their caregivers and public health. The concise guidelines focus on evidence-based recommendations and their practical implementation supported by clear figures and treatment pathways. The holistic care for AF patients including their comorbidities is prioritized in a comprehensive AF-CARE concept. It comprises “C” for comorbidities and risk factor management, “A” for avoidance of stroke and thromboembolism, “R” for reduction of symptoms by rate and rhythm control and “E”, evaluation and dynamic reassessment. Ablation is now the first-line therapy in paroxysmal AF. Current data on device detected AF and triggered AF are considered. Maximum involvement of the patient for informed, shared decision-making is suggested, supported by the parallel publication of patient guidelines.